All In Biotech

Drug Trial Radar · NCT07571135

Letermovir vs Valganciclovir in CMV R+ Kidney Transplant

Letermovir Versus Valganciclovir for 90 Days in CMV Seropositive Kidney Transplant Recipients: Results of a Single-center Experience.

Last checked: Nov 20, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

May 2026

Primary completion

Nov 2028

Study completion Nov 2028

Sponsor

Lead sponsor
Elisabeth KincaideGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
May 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to find out whether letermovir can help prevent cytomegalovirus (CMV) infection in kidney transplant recipients who are CMV seropositive. To do this, researchers will compare patients who received letermovir with a group of historical patients who received valganciclovir ("mini dose"). Both groups will be on CMV prophylaxis drug for 90 days post-transplant. The main question the study wants to answer is: • Does letermovir work as well as valganciclovir in preventing CMV infections during the first 12 months after a kidney transplant? The study will also look at other important questions: * Is letermovir easier for patients to tolerate than valganciclovir? * How long does it take for a CMV infection to appear in each group? * Are there differences in "breakthrough" CMV infections between the two medications? * For patients who develop CMV that becomes resistant to treatment, are the resistance patterns different between the two groups

Conditions

  • CMV Infection
  • CMV
  • CMV Viremia
  • CMV Disease

Interventions

  • LetermovirDrug

    Letermovir 480 mg PO daily or 240 mg PO daily (if on cyclosporine) for 90 days post kidney transplant

  • Valganciclovir CMV ProphylaxisDrug

    Valganciclovir 450 mg PO daily for 90 days post kidney transplant (Historical Control)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CMV InfectionTime frame: 12 months post kidney transplant

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Hospital

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.